Tecarfarin sodium is under clinical development by Cadrenal Therapeutics and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Tecarfarin sodium’s likelihood of approval (LoA) and phase transition for Bleeding And Clotting Disorders took place on 18 Oct 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tecarfarin sodium Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Tecarfarin sodium overview

Tecarfarin is under development for the treatment of bleeding and clotting disorders, venous thromboembolism and thrombosis. The drug candidate is administered through oral route. It is a small molecule. It is designed to have the same therapeutic benefits as the drug warfarin. Tecarfarin targets Vitamin K epoxide reductase (VKOR) enzyme. The drug candidate is designed based on retrometabolic drug design technology. The drug candidate was also under development as a anticoagulant for the treatment of blood clots formed in atrial fibrillation (AF), heart valve disease, and deep venous thromboembolism (DVT).

Cadrenal Therapeutics overview

Cadrenal Therapeutics is a biopharmaceutical company developing a late-stage novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin. Cadrenal Therapeutics is headquartered in Ponte Vedra, Florida, the US.

Quick View Tecarfarin sodium LOA Data

Report Segments
  • Innovator
Drug Name
  • Tecarfarin sodium
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Hematological Disorders
Key Developers
  • Sponsor Company: Cadrenal Therapeutics
  • Originator: ARYx Therapeutics
Highest Development Stage
  • Phase III


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.